Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-22
DOI
10.3389/fonc.2020.00669
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global phosphoproteomic analysis reveals ARMC10 as an AMPK substrate that regulates mitochondrial dynamics
- (2019) Zhen Chen et al. Nature Communications
- miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2
- (2019) Wenzheng Luo et al. LIFE SCIENCES
- Chemotherapeutic Stress Induces Transdifferentiation of Glioblastoma Cells to Endothelial Cells and Promotes Vascular Mimicry
- (2019) Shivani Baisiwala et al. Stem Cells International
- STC1 regulates glioblastoma migration and invasion via the TGF‑β/SMAD4 signaling pathway
- (2019) Yan Xiong et al. Molecular Medicine Reports
- miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme
- (2019) Kuo-Hao Ho et al. PHARMACOLOGICAL RESEARCH
- Stanniocalcin-1 augments stem-like traits of glioblastoma cells through binding and activating NOTCH1
- (2018) Yong Li et al. CANCER LETTERS
- Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
- (2018) Sabine Hombach-Klonisch et al. PHARMACOLOGY & THERAPEUTICS
- Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis
- (2018) Guo-zhong Yi et al. Biomed Research International
- Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy
- (2018) Xiudong Guan et al. Cell Death & Disease
- 20(S)‐ginsenoside‐Rg3 reverses temozolomide resistance and restrains epithelial‐mesenchymal transition progression in glioblastoma
- (2018) Zheng Chen et al. CANCER SCIENCE
- Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway
- (2018) Hua-Chao Yang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells
- (2017) Huijun Zeng et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- TERT promoter mutations in telomere biology
- (2017) Barbara Heidenreich et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis
- (2017) R. H. Dahlrot et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma
- (2017) Qi Liu et al. ONCOLOGY REPORTS
- Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas
- (2016) Ming-Yang Li et al. Scientific Reports
- A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
- (2016) Hideyuki Arita et al. Acta Neuropathologica Communications
- Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
- (2015) Khaled Messaoudi et al. DRUG DISCOVERY TODAY
- PTPRN2 and PLC 1 promote metastatic breast cancer cell migration through PI(4,5)P2-dependent actin remodeling
- (2015) C. A. Sengelaub et al. EMBO JOURNAL
- Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression
- (2015) Gloria Perazzoli et al. PLoS One
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
- (2013) A. D. Norden et al. NEURO-ONCOLOGY
- mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
- (2013) M. Weiler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
- (2011) Jaime Gállego Pérez-Larraya et al. JOURNAL OF CLINICAL ONCOLOGY
- NKX3.1 Activates Expression of Insulin-like Growth Factor Binding Protein-3 to Mediate Insulin-like Growth Factor-I Signaling and Cell Proliferation
- (2009) E. Muhlbradt et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More